

# Medigus Ltd

14:25 04 Mar 2019

## Medigus Ltd stock rockets after it cuts deal with Linkury to establish e-commerce platform for CBD products

Medigus Ltd (NASDAQ:MDGS) (TASE:MDGS) stock surged Monday after announcing it had entered into a pact with online advertising company Linkury Ltd, owned by Algomizer Ltd (TASE:ALMO), to establish an e-commerce site for cannabidiol or CBD-based products.

Shares in the medical device company shot up 22.1% to \$3.48 in premarket trade.

The two companies are looking at entering into a definitive agreement and forming an international advertisement company to carry out the joint venture.

READ: Arcadia Biosciences shares pop after receiving industrial hemp license in Hawaii

The Algomizer group has expertise in Internet video, sales, advertising, and website monetization. It has advanced technologies linked to developing algorithms in the field of artificial intelligence and business intelligence.

It specializes in internet marketing, serving large customers like Google parent Alphabet Inc (NASDAQ:GOOG), Microsoft Corporation (NASDAQ:MSFT), Apple Inc (NASDAQ:AAPL) and Instagram.

Under the memorandum of understanding, the two companies will invest in setting up an e-commerce platform and video site designed by Linkury, while Medigus takes care of the business side of things, including regulation related to CBD products. The companies will jointly invest up to \$500,000 in the venture for building infrastructure and will own it in equal parts.

Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

**Price:** 1.68

**Market Cap:** \$6.38 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDGS

**Listing:** NASDAQ

52 week	High	Low
	3.51	1.62

**Sector:** Cannabis

**Website:** [www.medigus.com](http://www.medigus.com)

### Company Synopsis:

Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions across medical and industrial applications. The company's vision is to enhance the advantages of disposable endoscopes and miniaturized direct vision systems to help improve patient outcomes and their quality of lives.

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.